Posted by Michael Wonder on 03 Aug 2021
DoH publishes revised agenda for Nov 2021 PBAC meeting
3 August 2021 - One week on and we are already up to version 3.
The Department of Health has published an updated version (version 3) of the agenda for the next scheduled PBAC meeting on the PBS website.
Version 3 has just one change - the addition of a submission from Novartis for omalizumab (Xolair). The submission seeks to combine the existing listings of 75 mg and 150 mg strengths to allow patients requiring 225 mg and 375 mg, respectively, to pay a single co-payment. Clearly one to watch out for in December.
